Genotropin Study Assessing Use of Injection Pen

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Growth Hormone DeficiencyIdiopathic Short Stature
Interventions
DEVICE

New Genotropin Pen

Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen

Trial Locations (25)

15218

Pfizer Investigational Site, Pittsburgh

19107

Pfizer Investigational Site, Philadelphia

21201

Pfizer Investigational Site, Baltimore

21229

Pfizer Investigational Site, Baltimore

29425

Pfizer Investigational Site, Charleston

29506

Pfizer Investigational Site, Florence

32308

Pfizer Investigational Site, Tallahassee

32608

Pfizer Investigational Site, Gainesville

32610

Pfizer Investigational Site, Gainesville

38105

Pfizer Investigational Site, Memphis

38119

Pfizer Investigational Site, Memphis

38671

Pfizer Investigational Site, Southaven

43205

Pfizer Investigational Site, Columbus

44308

Pfizer Investigational Site, Akron

46202

Pfizer Investigational Site, Indianapolis

64108

Pfizer Investigational Site, Kansas City

75230

Pfizer Investigational Site, Dallas

75235

Pfizer Investigational Site, Dallas

76104

Pfizer Investigational Site, Fort Worth

78229

Pfizer Investigational Site, San Antonio

80111

Pfizer Investigational Site, Greenwood Village

90048

Pfizer Investigational Site, Los Angeles

98105

Pfizer Investigational Site, Seattle

92123-4282

Pfizer Investigational Site, San Diego

07962

Pfizer Investigational Site, Morristown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00965484 - Genotropin Study Assessing Use of Injection Pen | Biotech Hunter | Biotech Hunter